NUCLEOLIN and cancer: We demonstrated that the aptamer AS1411 confers a selective targeting activity to Apt-NCs, when compared with pristine nanocages, showing a clear targeting preference for the nucleolin-positive HeLa cancer cells compared with the nucleolin-negative control cells.